Skip to main content

Mechanisms · Mechanism of Action

Noribogaine — The Long-Tail Metabolite

Noribogaine is ibogaine's CYP2D6-formed metabolite — cleaner mu-opioid partial-agonist profile, lower hERG signal, longer half-life. The molecule that drives the post-flood-dose tail.

DA
Medically reviewed by Dr. Arellano, M.D.
Clinical Director, MindScape Retreat · Board-certified physician specializing in ibogaine-assisted detoxification with over 1,000 patients treated.
Last reviewed: May 2026 · See full medical team

Quick Answer

What is noribogaine — the long-tail metabolite in ibogaine pharmacology?

Noribogaine (12-hydroxyibogamine) is the primary active metabolite of ibogaine, formed in vivo by hepatic CYP2D6 O-demethylation. It has a substantially longer plasma half-life than parent ibogaine, a cleaner mu-opioid partial-agonist profile, and a smaller hERG/QT signal — which is why some research programs have explored noribogaine alone as a development candidate. At MindScape, noribogaine is the molecule responsible for most of the post-flood-dose clinical tail and is the reason continuous cardiac telemetry extends 72-96 hours after dosing.

Reviewed by Dr. Arellano, M.D. — May 2026

Formation and disposition

Noribogaine is formed by CYP2D6-mediated O-demethylation of ibogaine, primarily in the liver. The conversion rate depends heavily on CYP2D6 metabolizer status (see the Pharmacokinetics deep-dive).

Once formed, noribogaine is highly lipophilic and accumulates in adipose tissue. Plasma elimination half-life estimates range from 28 to 49 hours, substantially longer than parent ibogaine.

Receptor profile differences from parent ibogaine

Compared to ibogaine, noribogaine has a cleaner pharmacological signature: stronger mu-opioid partial-agonist activity, kappa-opioid partial-agonist activity, serotonin transporter inhibition, and a notably smaller hERG/QT signal in cardiac assays.

These differences are why noribogaine has been explored as a stand-alone development candidate (Glue et al. 2015, 2016) — it preserves the long-tail anti-craving and mood-elevating effects while reducing the acute QT-prolongation risk that comes with parent ibogaine.

  • Mu-opioid receptor: partial agonist (cleaner than parent ibogaine).
  • Kappa-opioid receptor: partial agonist activity.
  • Serotonin transporter (SERT): inhibition — contributes to mood-elevating tail.
  • hERG channel: substantially smaller QT-prolongation signal.

Why telemetry extends 72-96 hours

Although parent ibogaine clears within 24-36 hours of the flood dose, noribogaine concentrations remain pharmacologically active for days. The MindScape cardiac telemetry window is calibrated to this metabolite tail — not to parent ibogaine elimination.

This is also why patients can describe sustained mood and anti-craving effects in the week after the flood dose: the noribogaine tail is doing the work.

Targets

  • Mu-opioid receptor (partial agonist)
  • Kappa-opioid receptor
  • Serotonin transporter (SERT)
  • hERG channel (low signal)
  • CYP2D6 substrate

Citations & Reading

  • Glue P, et al. (2015). Drug Metabolism and Disposition, 43(1), 119-125.
  • Glue P, et al. (2016). Clinical Pharmacology in Drug Development, 5(6), 460-468.
  • Mash DC, et al. (2018). Frontiers in Pharmacology, 9, 529.
  • Maillet EL, et al. (2015). Neuropharmacology, 99, 675-688.

For broader clinical context, see the 2026 evidence-base review and the onsite taper cohort methodology page.

Related mechanisms

Clinical Calls

Have a question about this mechanism?

Our medical team takes calls from prospective patients, family members, and referring clinicians.

Schedule a clinical call

100% Confidential · No Obligation